|
|
|
|
 |
 |
 |
|
 |
|
|
Breast and Ovarian Cancer Family Registries - Published Reports
|
|||||||||
|
|||||||||
Papers |
|||||||||
|
2004 Ahsan H, Chen Y, Whittemore AS, Kibriya MG, Gurvich I, Senie RT, Santella RM. A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat 2004;85(2):121-31. Beral V, Bull D, Doll R, Peto R, Reeves G; Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 2004;363(9414):1007-16. Easton DE and The CHEK2 Breast Cancer Consortium, comprising Dunning A, Tee L, Baines C, Healey K, Pharoah P, Ponder B, Eeles R, Sodha N, Stratton M, Rahman N, Peto J, Spurdle A, Chen X, Chenevix-Trench G, Hopper J, Nevanlinna H, Dork T, Devilee P, Meijers-Heijboer H, Schutte M. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;4:1175-82. Figueiredo JC, Knight JA, Briollais L, Andrulis IL, Ozcelik H. Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2004;13(4):583-91. Frost CJ, Venne V, Cunningham D, Gerritsen-McKane R. Decision-making with uncertain information: learning from women in a high risk breast cancer clinic. J Genet Couns 2004;13(3):221-36. Knight JA, Onay UV, Wells S, Li H, Shi EJQ, Andrulis IL, Ozcelik H. Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2004;13(1):146-149. Mancuso C, Glendon G, Anson-Cartwright L, Shi EJQ, Andrulis IL, Knight J. Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Ann Epidemiol 2004;14(1):36-43. Osborne RH, Elsworth GR, Sprangers MAG, Oort FJ, Hopper JL. The value of the Hospital Anxiety and Depression Scale (HADS) for comparing women with early onset breast cancer with population-based reference women. Qual Life Res 2004;13(1):191-206. Phillips KA, Milne RL, Friedlander ML, Jenkins MA, McCredie MR, Giles GG, Hopper JL. Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol 2004;22(4):699-705. Segal J, Esplen MJ, Toner B, Baedorf S, Narod S, Butler K. An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers. Am J Med Genet 2004;125A(3):267-72. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR,
Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore
AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard
J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H. Are
ATM mutations 7271T Yang WL, Godwin AK, Xu XX. Tumor
necrosis factor-alpha-induced matrix proteolytic enzyme production and
basement membrane remodeling by human ovarian surface epithelial cells:
molecular basis linking ovulation and cancer risk. Cancer Res
2004;64(4):1534-40. 2003 Ahsan H. Placental genes and breast cancer: Can the offspring's or father's genotypes be predictive of mother's risk? Epidemiology 2003;14(2):251-3. Ahsan H, Rundle AG. Measures of genotype versus gene products: promise and pitfalls in cancer prevention. Carcinogenesis 2003;24(9):1429-34. Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey M, Venter DJ, Hopper JL. Log odds of carrying an ancestral mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 2003;5(6):R206-R216. Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, Green A, Healey CS, Redman K, Dunning AM, Pharoah PD, Easton D, Ponder BAJ, Chenevix-Trench G, Novik KL. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Cancer Res 2003;103(3):427-30. Burrows JF, Chanduloy S, McIlhatton MA, Nagar H, Yeates K, Donaghy P,
Price J, Godwin AK, Johnston PG, Russell SEH. Altered
expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol
2003 Dec;201(4):581-588. Capo-chichi CD, Roland IH, Vanderveer L, Bao R, Yamagata T, Hirai H, Cohen C, Hamilton TC, Godwin AK, Xu XX. Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res 2003;63(16):4967-77. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D’Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003;100(10): 5956-61. Cui JS, Spurdle AB, Southey MC, Dite GS, Venter DJ, McCredie MRE, Giles
GG, Chenevix-Trench G, Hopper JL. Regressive
logistic and proportional hazards disease models for within-family analyses
of measured genotypes, with application to a CYP17 polymorphism and breast
cancer. Genet Epidemiol 2003;24(3):161-72. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MRE,
Venter DJ, Hopper JL. Familial
risk, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.
J Natl Cancer Inst 2003;95(6):448-57. Dong Y, Hakimi M-A, Chen X, Cooch NS, Westermark U, Godwin AK, Shiekhattar R. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell 2003;12(5):1087-99. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003;2(8):699-709. Gong G, Whittemore AS. Optimal
designs for estimating penetrance of rare mutations of a disease-susceptibility
gene. Genet Epidemiol 2003;24:173-80. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003;63(3):664-73. Hopper JL. Commentary: case-control-family designs: a paradigm for future epidemiology research? Int J Epidemiol 2003;32(1):48-50. McCredie MR, Dite GS, Southey MA, Venter DJ, Giles GG, Hopper JL. Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. Br J Cancer 2003;89(9):1661-3. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, Suga M, Matsumoto M, Wong AJ. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003;94(1):50-6. Osborne RH, Elsworth GR, Hopper JL. Age-specific
norms and determinants of anxiety and depression in 731 women with breast
cancer recruited through a population cancer registry. Eur J Cancer
2003;39(6):755-62. Ozcelik H, Knight JA, Glendon G, Yazici H, Carson N, Ainsworth PJ, Taylor
SAM, Feilotter H, Carter RF, Boyd NF, Andrulis IL. Individual
and family characteristics associated with BRCA1 and BRCA2 mutations in
an Ontario population-based series from the Cooperative Family Registry
for Breast Cancer Studies. J Med Gen 2003;40(8):E91. Pharaoh PD, Antoniou A, Hopper JL, Easton DF. Re: On the use of familial aggregation in population-based case probands for calculating penetrance (correspondence). J Nat Cancer Inst 2003;95(1):75-6. Prowse A, Schultz DC, Guo S, Vanderveer L, Dangel J, Bove B, Cairns P, Daly M, Godwin AK. Identification of a novel splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. J Med Genet 2003;40(8):e102. Roland IH, Yang W-L, Yang D-H, Daly M, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX. Loss of surface and cyst epithelial basement membranes and preneoplastic morphological changes in prophylactic oophorectomies. Cancer 2003;98(12):2607-23. Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 2003 May;112(5-6):542-51. Venne VL, Botkin JR, Buys SS. Professional opportunities and responsibilities in the provision of genetic information to children relinquished for adoption. Am J Med Genet 2003;119A(1):41-6. Wagner C, Itzen M, Malick J, Babb JS, Bove B, Godwin AK, Daly MB. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet 2003;119C:11-18. Whittemore AS, Gong G. On the use of familial aggregation in population-based
case probands for calculating penetrance (letter). J Natl Cancer Inst
2003;95:76-7. 2002 Ahsan H, Hodge SE, Heiman GA, Begg MD, Susser ES. Relative
risk for genetic associations: The case-parent triad as a variant of case-cohort
design. Int J Epidemiol 2002;31(3):669-78. Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK,
Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey
MC, Van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS. Comparison
of DNA- and RNA-based methods for detection of truncating BRCA1 mutations.
Hum Mutat 2002;20(1):65-73. Cappelli M, Hunter AG, Stern H, Humphreys L, Van Houten L, O’Rourke K, Viertelhausen S, Perras H, Lagarde A. Participation rates of Ashkenazi Jews in a colon cancer community-based screening/prevention study. Clin Genet 2002 Feb;61(2):104-14. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork, T., Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann G, Khanna KK. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002;94(3):205-15. Collaborative Group on Hormonal Factors in Breast Cancer. Breastfeeding and breast cancer: Collaborative reanalysis of individual data from 47 epidemiological studies including 50,302 women with breast cancer and 96,973 women without breast cancer from 30 countries. Lancet 2002;360:187-95. Cotterchio M, Nadalin V, Sauer M. Human breast cancer and lymphomas may share a common aetiology involving Mouse Mammary Tumour Virus (MMTV). Med Hypotheses 2002;59(4):492-4. Review. Esplen MJ. A supportive-expressive group intervention in BRCA1 and BRCA2. French Review of Psycho-Oncology 2002;(4):54-60. Esplen MJ, Hunter J, Narod S, Warner E, Leszcz M, Liede A, Butler K. Baseline distress among women testing positive for BRCA1/2 participating in a supportive-expressive group therapy intervention. J Clin Oncol January 2002. Frolov A, Prowse AH, Vanderveer L, Bove B, Wu H, Godwin AK. DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer 2002;35(3):232-41. Hamajima N, Hirose K, Tajima K, Hopper JL, McCredie MRE. Alcohol, tobacco, breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87(11):1234-45. Jarjanazi H, Ozcelik H. Modified rapid expansion detection method to analyze CAG/CTG repeat expansions. Biotechniques 2002;35(5):1006-10.
Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL. Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. Ann Epidemiol 2002;12(1):27-33. Motykiewicz G, Faraglia B, Wand L, Terry MB, Senie RT, Santella RM. Removal of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts as a measure of DNA-repair capacity in lymphoblastoid cell lines from sisters discordant for breast cancer. Environ Mol Mutagen 2002;40(2):93-100. Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight J, Goodwin PJ, Andrulis IL. O'Malley F. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA-1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002;95(10):2068-75. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MRE, Giles GG, Chenevix-Trench G, Liddle C. The cytochrome P450 3A4 5' nifedipine-specific response element polymorphism has no apparent functional significance and is not associated with risk of breast or ovarian cancer in Australian women. Pharmacogenetics 2002;12(5):355-66. Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, Giles GG, Ellis-Steinborner S, Venter DJ, Newman B, Southey MC, Chenevix-Trench G. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2002;11(4):413-6. Spurdle AB, Hopper JL, Chen X, McCredie MRE, Giles GG, Newman B, Chenevix-Trench G. Prohibitin 3' untranslated region polymorphism and breast cancer risk in Australian women. Lancet 2002;360(9337):925-6. Spurdle AB, Hopper JL, Chen X, McCredie MRE, Giles GG, Newman B, Chenevix-Trench G, Khanna KK. No evidence for association of ATM T2119C and C3161G amino acid substitution polymorphisms with breast cancer. Breast Cancer Res 2002;4(6):R15. Spurdle AB, Hopper JL, Chen X, McCredie MRE, Giles GG, Venter DJ, Southey MC, Chenevix-Trench G. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2002;11(5):439-43. Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, Renard H, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, Peretz T, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olah E, Bignon YJ, Ruiz P, Badzioch MD, Vasen HF, Futreal AP, Phelan CM, Narod SA, Lynch HT, Ponder BA, Eeles RA, Meijers-Heijboer H, Stoppa-Lyonnet D, Couch FJ, Eccles DM, Evans DG, Chang-Claude J, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE, Stratton MR; KConFab Consortium. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002;99(2):827-31. Venne VL, Smith JA. What do we share? Developing informed consent with teens to join a familial cancer registry. Joint Commission Benchmark 2002;4(1):6-7. Yazici H, Glendon, G, Yazici H, Burnie SJ, Saip P, Buyru, F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 (2002) Mutations in Turkish familial and non-familial ovarian cancer patients: A high incidence of mutations in non-familial cases. Hum Mutat 2002(1):28-34. 2001 Beck JC, Beiswanger CM, John EM, Satariano E, West D. Successful transformation of cryopreserved lymphocytes: A resource for epidemiological studies. Cancer Epidemiol Biomarkers Prev 2001;10(5):551-4. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease (review). Lancet 2001;358(9291):1389-99. Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MR, Hopper JL. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 2001;68:420-31. Di Prospero L, Seminsky M, Honeyford J, Doan B, Meschino W, Chart P, Warner E. Psychosocial issues following a positive genetic test for BRCA1 and BRCA2: Findings from a focus group and a needs assessment survey. CMAJ 2001;64(7):1005-9. Esplen MJ, Hunter J, Hanna D, Liede A, Leszcz M, Madlensky L, Butler K, Glendon G. Description of a supportive-expressive group psychotherapy intervention for women identified as BRCA1/2 carriers. Int J Group Ther. December 2001. Hopper JL. Genetic epidemiology of female breast cancer. Semin Cancer Biol 2001;11(5): 367-74. Koenig BA. Why not grant primacy to the family? (Commentary) Am J Bioeth 2001;1(3):33-4. Kreiger N, Ashbury F, Cotterchio M, Macey J. A qualitative study of subject recruitment for familial cancer research. Ann Epidemiol 2001;11:219-24. McCredie MR, Dite GS, Porter L, Maskiell J, Giles GG, Phillips KA, Redman S, Hopper JL. Prevalence of self-reported arm morbidity following treatment for breast cancer in the Australian Breast Cancer Family Study. The Breast 2001;10(6):515-22. Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, Chenevix-Trench G. The steroid 5 alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2001;10(12):1287-93. Sutherland HJ, Lacroix J, Knight J, Andrulis IL, Boyd NF, the Ontario Cancer Genetics Network. The Cooperative Familial Registry for Breast Cancer Studies: Design and first year recruitment rates in Ontario. J Clin Epidemiol 2001;54:93-98. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001;10(9):955-60. 2000 Bordeleau L, Glendon G., Contiga V, Goodwin PJ. Descriptive study on
the use of prophylactic surgery in women with known BRCA mutations: The
Mount Sinai Hospital experience. Breast Cancer Res Treat 2000;64:518. Daly MB, Offit K, Li F, Glendon G, Yaker A, West D, Koenig B, McCredie, MD, Venne V, Nayfield S, Seminara D. Participation in the Cooperative Family Registry for Breast Cancer Studies (CFRBCS): Issues of informed consent. J Natl Cancer Inst 2000;92:452-6. Esplen MJ, Toner B, Hunter J, Glendon G, Liede A, Narod S, Stuckless N, Butler K, Field B. A supportive-expressive group intervention for women with a family history of breast cancer: Results of a phase II study. Psychooncology 2000:9(3):243-252. Gilpin C, Carson N, Hunter AGW. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 2000;58:299-308. Goodwin PJ. Management of familial breast cancer risk. Breast Cancer Res Treat 2000;62(1):19-33. Harmston GE, Scaife C, Buys S, Glenn M, Hart M, Burt RW. Colonoscopy screening in individuals with BRCA1 gene mutation. Am J Gastroenterol 2000;95(9):2535. Phillips KA, Warner E, Meschino W, Hunter J, Abdolell M, Glendon G, Andrulis IL, Goodwin PJ. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clin Genet 2000;57:376-83. Press N, Fishman JR, Koenig BA. Collective fear, individualized risk: the social and cultural context of genetic screening for breast cancer. Nurs Ethics 2000;7(3):237-49. Senie R, Santella R, Ahsan H. The Metropolitan New York Registry & CFRBCS: Unique resources for breast cancer research. Ann Epidemiol 2000;10(7):462. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MRE, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2000;92(20):1674-81. Tu IP, Balise RR, Whittemore AS. Detection of disease genes by use of family data. II. Applications to nuclear families. Am J Hum Genet 2000;66(4):1341-50. Whittemore AS, Tu IP. Detecting disease genes using family data. I. Likelihood-based theory. Am J Hum Genet 2000;66(4):1328-40. Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000;83(6):737-42. 1999 Armes JE, Trute L, White D, Southey MC, Hammett F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study. Cancer Res 1999;59(8):2011-7. Carroll JC, Heisey R, Warner E, Goel V, McCready D. Hereditary breast cancer: Psychosocial issues and the role of the family physician. Can Fam Physician 1999;45:126-32. Chan PC, Wong BYL, Ozcelik H, and Cole DEC. Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR. Clin Chem 1999;45(8):1285-87. Foulkes WD, Brunet JSB, Warner E, Goodwin PJ, Meschino W, Narod SA, Goss PE, Glendon G. The importance of a family history of breast cancer in predicting the presence of a BRCA mutation (correspondence). Am J Hum Genet 1999;65:1776-9. Heisey RE, Carroll JC ,Warner E, McCready DR, Goel V. Hereditary breast cancer: Identifying and managing BRCA1 and BRCA2 carriers. Can Fam Physician 1999;45:114-24. Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG. Design and analysis issues in a population-based-case-control-family study of the genetic epidemiology of breast cancer and the Cooperative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr 1999;26:95-100. Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF, Poon CS, Leung YF, Loong F, Ip P, Chan GS, Andrulis IL, Lu J, Ho FC. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 1999;18(32):4643-6. Ondrusek N, Warner E, Goel V. Development of a knowledge scale about breast cancer and heredity (BCHK). Breast Cancer Res Treat 1999;53:69-75. Osborne RH, Elsworth GR, Kissane DW, Burke SA, Hopper JL. The Mental Adjustment to Cancer (MAC) scale: replication and refinement in 632 breast cancer patients. Psychol Med 1999;29(6):1335-45. Ozcelik H, Nedelcu R, Chan VWY, Shi X-H, Murphy J, Rosen B, Andrulis IL. Mutation in the coding region of the BRCA1 gene leads to aberrant splicing of the transcript (correspondence). Hum Mutat 1999;14:540-1. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? (review) J Clin Oncol 1999;17:3653-63. Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Andrulis IL. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 1999;91:469-73. Phillips KA, Glendon G, Knight J. Putting the risk of breast cancer in perspective. N Engl J Med 1999;340:141-4. Seminara D, ed. Innovative study designs and analytic approaches to the genetic epidemiology of cancer. J Natl Cancer Inst Monograph 1999;26:1-105. Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, Hopper JL, Chenevix-Trench G. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 1999;91(11):961-6. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Patterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, DiProspero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet J-S, Narod S. Prevalence and penetrance of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7. Warner E, Goel V, Ondrusek N, Thiel E, Lickley L, Chart P, Meschino W, Doan B, Carroll J, Taylor K. Pilot study of an information aid for women with a family history of breast cancer. Health Expect 1999;2:118-28. Warner E, Heisey RE, Goel V, Carroll JC, McCready DR. Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. Can Fam Physician 1999 Jan;45:104-12. 1998 Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. The histologic phenotypes of breast carcinoma occurring before age 40 in women with and without BRCA1 or BRCA2 germline mutations: A population-based study. Cancer 1998;83(11):2335-45. Done SJ, Arneson NCR, Ozcelik H, Redston M, Andrulis IL. p53 Mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 1998;58:785-9. Esplen MJ, Toner B, Hunter J, Glendon G, Butler K, Field B. A group therapy approach to facilitate integration of risk information for women at risk for breast cancer. Can J Psychiatry 1998;43:375-80. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Millineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16(7):2417-25. Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, Steele L, Avizonis V, Stewart JR, Cannon-Albright LA. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998;47(2):129-36. Hoffman JD, Hallam SE, Venne VL, Lyon E, Ward K. Implications of a novel cryptic splice site in the BRCA1 gene. Am J Med Genet 1998;80(2):140-4. Erratum in: Am J Med Genet 1999;82(1):101. Koenig BA, Greely HT, McConnell LM, Silverberg HL, Raffin TA. Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group. J Womens Health 1998;7(5):531-45. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 1998;29(10):1140-4. Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Intl J Cancer 1998;77:1-6. Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King MC, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APC l1307K allele and breast cancer risk (correspondence). Nature Genet 1998;20:13-4. To MD, Done SJ, Redston SJ, Andrulis IL. Analysis of mRNA from microdissected frozen tissue sections without RNA isolation. Am J Pathol 1998;153:47-51. 1997 Andrulis IL, Boyd NF, Sutherland H. New Ontario familial breast cancer registry to facilitate genetic and epidemiologic studies. Can Fam Physician 1997;43:949-50. Ozcelik H, Schmocker B, Di Nicola N, Shi X-H, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients (correspondence). Nature Genet 1997;16:17-8. 1996 Barker DF, Almeida ER, Casey G, Fain PR, Liao SY, Masunaka I, Noble B, Kurosaki T, Anton-Culver H. BRCA1 R841W: A strong candidate for a common mutation with moderate phenotype. Genet Epidemiol 1996 13(6):595-604. Ozcelik H, Antebi YJ, Cole DE, Andrulis IL. Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation. Hum Genet 1996;98(3):310-2. |
|||||||||
Pilot Studies |
|||||||||
|
2000 Delfino RJ, Sinha R, Smith C, West J, White E, Lin HJ, Liao SY, Gim JS, Ma HL, Butler J, Anton-Culver H. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis 2000;21(4):607-15. Delfino RJ, Smith C, West J, White E, Lin HJ, Liao SY, Gim JS, Ma HL, Butler J, Anton-Culver H. Breast cancer, passive and active cigarette smoking and N-acetyltranferase 2 genotype. Pharmacogenetics 2000;10(5):461-9. Ziogas A, Gildea M, Cohen P, Bringman D, Taylor TH, Seminara D, Barker D, Casey G, Haile R, Liao SY, Thomas D, Noble B, Kurosaki T, Anton-Culver H. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9(1):103-11. 1999 Astin JA, Anton-Culver H, Schwartz C, Shapiro DH, McQuade J, Breuer A, Taylor T, Lee H, Kurosaki T. Sense of control and adjustment to breast cancer: the importance of balancing control coping styles. Behav Med 1999;25(3):101-9. Boyer-Chammard AB, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev 1999;23(6):463-73. Janezic SA, Ziogas A, Krumroy LM, Krasner M, Plummer SJ, Cohen P, Gildea M, Barker D, Haile R, Casey G, Anton-Culver H. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet 1999;8(5):889-97. 1998 Bentley JR, Delfino RJ, Taylor TH, Howe S, Anton-Culver H. Differences in breast cancer stage at diagnosis between non-Hispanic white and Hispanic populations, San Diego County 1988-1993. Breast Cancer Res Treat 1998;50(1):1-9. 1997 Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton-Culver H. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60(2):313-9. Re A, Taylor TH, DiSaia PJ, Anton-Culver H. Risk for breast and colorectal cancers subsequent to cancer of the endometrium in a population-based case series. Gynecol Oncol 1997;66(2):255-7. 1996 Anton-Culver H, Kurosaki T, Taylor T, Gildea M, Brunner D, Bringman D. Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry. Genet Epidemiol 1996;13(2):193-205. Barker DF, Almeida ER, Casey G, Fain PR, Liao SY, Masunaka I, Noble B, Kurosaki T, Anton-Culver H. BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. Genet Epidemiol 1996;13(6):595-604. DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174(5):1494-8. 1995 Plummer SJ, Anton-Culver H, Webster L, Noble B, Liao S, Kennedy A, Belinson J, Casey G. Detection of BRCA1 mutations by the protein truncation test. Hum Mol Genet 1995;4(10):1989-91. |
|||||||||
Meeting Abstracts |
|||||||||
|
2003 Altomere DA, Wang HQ, De Rienzo A, Skele KL, Klein-Szanto JP, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. 11th Annual SPORE Investigator's Workshop, Baltimore, MD, 2003 (abstract 92a). Bassi DE, Lopez De Cicco R, Alexander P, Godwin AK, Klein-Szanto A. Elevated furin expression in ovarian tumors. Proc Am Assoc Cancer Res 2003;44:3369. Bosnoyan-Collins L, Gokgoz N, Arneson N, He W, Woodgett J, Done S, Bull SB, Andrulis IL. Chromosomal aberrations and gene expression in breast cancer using microarray analysis. Annual Meeting of the American Association for Cancer Research, 2003. Esplen MJ, Ardiles P, Stuckless N, Hunter J, Glendon G, Liede A, Metcalfe K, Aronson M, Butler K, Rothenmund H, Berk T, Lefebvre A. Self-concept instrument development among individuals testing positive for genetic mutations in cancer. Psycho-Oncology 2003;12(4 suppl):S230. Esplen MJ, Hunter J. Loss and grief in women with BRCA1/2 mutations participating in a supportive-expressive group intervention study. Psycho-Oncology 2003;12(4 suppl):A175. Frolov A, Arnoletti JP, Pan ZZ, Fletcher J, Favorova O, von Mehren M, Eisenberg B, Godwin AK. Sprouty 4A: a novel diagnostic marker of response to Gleevec (STI-571) in gastrointestinal stromal tumors. Society of Surgical Oncology 56th Annual Cancer Symposium, Los Angeles, CA, March 5-9, 2003;10:S8 (abstract 3a) (selected for oral presentation). Frolov A, Chahwan S, Pan Z-Z, Fletcher J, Favorova O, von Mehren M, Eisenberg B, Godwin AK. Gleevec and gastrointestinal stromal tumors (GISTs): identification of response markers and the molecular mechanisms of action. Proc Am Assoc Cancer Res 2003;44:950 (selected for oral presentation). Godwin AK, Kiviat N, Schummer M, Hamilton TC, Urban N. Analysis of preneoplastic lesions of the ovary. 11th Annual SPORE Investigator's Workshop, Baltimore, MD, 2003 (abstract 74a). Guo S-C, Godwin AK. Accumulation of p84N5 domain protein is associated with an aggressive phenotype of human breast tumors. Proc Am Assoc Cancer Res 2003;44:2421. Hendry SL, Andrulis IL. Investigation of the interaction of BRCA1 and
protein phosphatase 1 Kennedy DO, Agrawal M, Shen J, Zhang FF, Terry MB, Senie RT, Santella RM. DNA repair capacity via removal of benzo[a]pyrene diolepoxide (BPDE)-DNA adducts in lymphoblastoid cell lines from sisters discordant for breast cancer. American Association for Cancer Research 2003:A1487. Neuhausen SL, Lynch HT, Weber BL, Garber JE, Daly MB, Godwin AK, Wagner T, Nathanson K, Farnham J, Narod SA, Rebbeck TR. Modification of BRCA1- and BRCA2-associated breast and ovarian cancer risk by RAD51. Proc Am Assoc Cancer Res 2003;44:574 (selected for oral presentation). Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio U, Saya H, Wong AJ. Proteolytic cleavage of CD44 adhesion molecule in multiple human tumors. Proc Am Assoc Cancer Res 2003;44:4090. Pan Z-Z, Godwin AK. -Synuclein may render cancer cell resistance to paclitaxel by activating AKT. Proc Am Assoc Cancer Res 2003;44:2031. Peacock S, Apicella C, Australian Jewish Breast Cancer Study. A stated preference discrete choice model of preferences for genetic counselling in Australian Jewish Breast Cancer Study participants. The 3rd Health Services Research and Policy Conference of Australia and New Zealand, Melbourne, Australia, November 15-19 2003. Roland I, Yang W-L, Yang D-H, Daly MB, Ozols RF, Hamilton TC, Godwin AK, Xu XX. Loss of surface and cyst epithelial basement membranes and pre-neoplastic morphological changes in prophylactic oophorectomies. 11th Annual SPORE Investigator's Workshop, Baltimore, MD, 2003 (abstract 96a) (selected for oral presentation). Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand J, Lessin S, Seykora J. Pleiotrophin expression correlates with melanocytic tumor progression. Annual Meeting of the American Society of Dermatopathology, Chicago, IL, October 9-12, 2003 (selected for oral presentation). 2002 Beck JC, Bender PK, Beggs W, John EM, Satariano E, West D. Effect of collection conditions of DNA yield from mouthwash. American Association for Cancer Research Proceedings 2002, abstract 263. Frolov A, Arnoletti JP, Pan ZZ, Fletcher J, Chahwan S, Fletcher J, Favorova O, von Mehren M, Eisenberg B, Godwin AK. Genocentric approach to determine response markers to Gleevec using an in vitro model for gastrointestinal stromal tumors. GIS MD Anderson Cancer Center 2nd Gastrointestinal Cancer Research Conference, Orlando, FL, November 20-23, 2002, (abstract 5a) (travel award, selected for oral presentation). Frolov A, Arnoletti JP, Pan ZZ, Fletcher J, Favorova O, von Mehren M, Eisenberg B, Godwin AK. Sprouty 4A: a novel diagnostic marker of response to Gleevec (STI-571) in gastrointestinal stromal tumors. Seventh Annual Postdoctoral Research Conference, Philadelphia, PA, 2002. Gokgoz N, Collins-Bosnoyan L, He W, Bull SB, Andrulis IL. Gene expression analysis of breast cancer using microarray technology. Oncogenomics 2002. He W, Shelley B, Gokgoz N, Andrulis IL, Wunder J. Application of reliability coefficients to assess normalization procedures in microarray data analysis. Oncogenomics 2002. Hendry SL, Andrulis IL. Analysis of the interaction of BRCA1 with protein phosphatase 1ß. Proc Amer Assoc Cancer Res 2002;43:4900. Terry MB, Dranick JA, Senie RT, Wang Q,j Santella RM. Alcohol intake and metabolism among women at high risk for breast cancer. Am J Epidemiol 2002;155: S14:05. 2001 Glendon GD, Ozcelik H, Knight JA, Carson N, Ainsworth P, Taylor S, Carter R, Boyd NF, Andrulis IL. BRCA1 and BRCA2 genotyping of cases ascertained in year one of the population-based Ontario Familial Breast Cancer Registry. Am J Hum Genet 2001;69(suppl, abstract 381). Motykiewicz G, Faraglia B, Senie RT, Santella RM. Post-treatment loss of BPDE-DNA adducts as a measure of DNA repair in human lymphoblasts. American Association for Cancer Research Proceedings 2001. Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight J, Goodwin PJ, Andrulis IL, O’Malley FP. HER2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA-1 mutation status in the OFBCR. San Antonio Breast Cancer Symposium 2001, abstract 404. Senie R, Andrulis I, Daly M, Hopper J, Buys S, West D, Anton-Culver H. A unique resource for breast cancer research: The Cooperative Family Registry for Breast Cancer Studies. Eur J Hum Gene 2001;9 Suppl 1:273. 2000 Esplen MJ, Stuckless N, Hunter J, Liede A, Metcalfe D, Narod S, Glendon G. The development of a self-concept scale for BRACA1 and BRACA2 carriers. Fifth World Congress of Psycho-Oncology. Melbourne, Australia. September 4, 2000 Psycho-Oncology 2000;9(5 Suppl):A14. Esplen MJ, Butler K, Madlensky L, Wong J, Aronson M, Gallinger S. Motivations and psychosocial impact of genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC). Psycho-Oncology 2000;9(5 Suppl):A323. 1999 Esplen MJ, Hunter J, Leszcz M, Toner B, Glendon G, Liede A. Supportive-expressive
group therapy interventions for individuals at genetic predisposition
for cancer. Psycho-Oncology 1999;8(6 Suppl):9. Hunter J, Esplen MJ, Toner B, Glendon G, Butler K, Field B. Stress response in women with a family history of breast cancer: baseline scores and response to therapy. Academy of Psychosomatic Medicine Proceedings 1999, p.13. 1998 Phillips KA, Hunter J, Warner E, Meschino W, Glendon G, Andrulis IL, Goodwin PJ. Factors Influencing the Decision to Undergo BRCA 1/2 Gene Testing: A Study of Ashkenazi Jewish Women With a Personal History of Breast Cancer (BC), Enrolled in an Ontario Cancer Genetics Network Protocol. American Society of Clinical Oncology Proceedings1998:17:558A, abstract 2141. Phillips, K.A., Özçelik, H., Redston, M.S., Goodwin, O.J., Knight, J., Andrulis, I.L. p53 mutations in breast cancer carcinomas of women with germline mutations in BRCA1. 1998. Meeting: Controversies in the Etiology, Detection and Treatment of Breast Cancer: University of Toronto, Dept of Continuing Education. |
|||||||||
Book Chapters |
|||||||||
|
Andrulis IL, Gokgoz N, Bull SB. Characterization of gene expression patterns
for classification of breast carcinomas in expression profiling of human
tumors: diagnostic and research applications. In: Ladanyi M, Gerald W,
eds. Expression Profiling of Human Tumors: Diagnostic and Research Applications.
Humana Press, 2003, pp. 121-45. B-TO-0597-021 Bentley JR, Delfino RJ, Taylor TH, Howe S, Anton-Culver H. Differences in breast cancer stage at diagnosis between non-Hispanic white and Hispanic populations, San Diego County 1988-1993. Breast Cancer Res Treat 1998;50(1):1-9. Esplen MJ. Hereditary cancer: fertile ground for collaborative care. In: Primary Psychiatry: Cancer Care Therapy: Psychosocial Issues in Cancer Genetics, Vol 5, May 2002. B-TO-0899-01 Ozcelik H, Glendon G. BRCA1 and BRCA2, breast cancer predisposition genes. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC: AACC Press, 2002. Squire J, Ozcelik H, Andrulis IL. Investigating the genetics of cancer. In: Oxford Textbook of Oncology. 2nd ed. Oxford University Press, 2002. Breast Cancer Family Registry3 Venne VL, Buys SS. Genetic testing for breast cancer predisposition. In: Jatoi I, ed. Manual of Breast Diseases. Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 459-78. Breast Cancer Family Registry3 Koenig BA, Stockdale AS. The promise of molecular medicine in preventing disease: examining the burden of genetic risk. In: Callahan D, ed. Health Promotion and Disease Prevention: Ethical and Social Dilemmas. Washington, DC: Georgetown University Press, 2000, pp. 116-37. B-SF-1196-011 Malkin D, Ozcelik H. Techniques in molecular biology. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Disease of the Breast. 2nd ed. Philadelphia: JB Lippincott Co., 1999, pp. 1069-84. General Methodology5 Ritvo P, Murphy KH, Rosen B, Cole D, et al. Psycological adjustment to familial genetic risk assessment: differences in two longitudinal samples. Elsevier Science Ireland Ltd., 1999. Breast Cancer Family Registry3 |
|||||||||
|
Search | Help | Contact Us | Accessibility |
G
and IVS10-6T
.
Proc Am Assoc Cancer Res (1st Ed) 2003;44:4949.